Anzeige
❌
Mehr »
Mittwoch, 18.11.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Quantensicherheit! Ist diese Aktie noch völlig unterschätzt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PP

WKN: A40GMU | ISIN: US71880W5013 | Ticker: 44R1
NASDAQ
17.11.26 | 21:58
0,703 US-Dollar
-2,05 % -0,015
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PHIO PHARMACEUTICALS CORP Chart 1 Jahr
5-Tage-Chart
PHIO PHARMACEUTICALS CORP 5-Tage-Chart

Aktuelle News zur PHIO PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series136Highlighting Phio's Differentiated, Paradigm-Shifting Treatment Approach for Skin CancerLive Presentation and Q&A: Wednesday, November 18, 2026 2 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp....
► Artikel lesen
10.11.Phio Pharmaceuticals: Third Quarter 2026 Results Highlight PH-762 Development Milestones And Progress Toward Phase 2b Study1
09.11.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting230INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of Prussia, Pennsylvania--(Newsfile Corp. - November...
► Artikel lesen
06.11.Phio Pharmaceuticals to present Phase 1b trial data at SITC1
06.11.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)450INTASYL siRNA - Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO)...
► Artikel lesen
05.11.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation274PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents...
► Artikel lesen
05.11.Phio Pharmaceuticals Corp. - 10-Q, Quarterly Report1
PHIO PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.11.Phio Pharmaceuticals Corp. - 8-K, Current Report1
19.10.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series414Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA...
► Artikel lesen
13.10.Phio Pharmaceuticals Corp. - 8-K, Current Report4
13.10.Phio Pharmaceuticals completes first commercial-scale PH-762 batch6
13.10.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance211Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026)...
► Artikel lesen
08.10.Phio Pharmaceuticals forciert Hautkrebsprogramm PH-76214
06.10.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026245Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.comKing of Prussia, Pennsylvania--(Newsfile Corp. - October 6...
► Artikel lesen
05.10.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference300Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - October...
► Artikel lesen
28.09.Phio Pharmaceuticals Corp. - 8-K, Current Report27
23.09.Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference371Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:...
► Artikel lesen
14.09.Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma3
14.09.Phio Pharmaceuticals Corp. - 8-K, Current Report1
14.09.Phio Pharmaceuticals submits FDA briefing for PH-762 study5
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1